-
Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-12 Elena Brozos-Vázquez, Marta Toledano-Fonseca, Nicolás Costa-Fraga, María Victoria García-Ortiz, Ángel Díaz-Lagares, Antonio Rodríguez-Ariza, Enrique Aranda, Rafael López-López
Pancreatic cancer is one of the tumors with the worst prognosis, and unlike other cancers, few advances have been made in recent years. The only curative option is surgery, but only 15–20% of patients are candidates, with a high risk of relapse. In advanced pancreatic cancer there are few first-line treatment options and no validated biomarkers for better treatment selection. The development of targeted
-
Clinical Management, Monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-11 Rebecca S. Heist, Jacob Sands, Aditya Bardia, Toshio Shimizu, Aaron Lisberg, Ian Krop, Noboru Yamamoto, Takahiro Kogawa, Saba Al-Hashimi, Simon S.M. Fung, Anat Galor, Francesca Pisetzky, Priyanka Basak, Cindy Lau, Funda Meric-Bernstam
Antibody drug conjugates (ADCs) are an emerging class of treatments designed to improve efficacy and decrease toxicity compared with other systemic therapies through the selective delivery of cytotoxic agents to tumor cells. Datopotamab deruxtecan (Dato-DXd) is a novel ADC comprising a topoisomerase I inhibitor payload and a monoclonal antibody directed to trophoblast cell-surface antigen 2 (TROP2)
-
Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-11 A. Kyriazoglou, A. Pagkali, I. Kotsantis, P. Economopoulou, M. Kyrkasiadou, M. Moutafi, N. Gavrielatou, M. Anastasiou, A. Boulouta, A. Pantazopoulos, M. Giannakakou, A. Digklia, A. Psyrri
Well-differentiated liposarcomas (WDLPS) and dedifferentiated liposarcomas (DDLPS) account for 60 % of all liposarcomas, reflecting the heterogeneity of this type of sarcoma. Genetically, both types of liposarcomas are characterized by the amplification of and genes, which indicates an important molecular event with diagnostic and therapeutic relevance. In both localized WDLPS and DDLPS of the retroperitoneum
-
How to manage waldenström’s macroglobulinemia in 2024 Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-05 Alexander Grunenberg, Christian Buske
Clinical management of Waldenström’s Macroglobulinemia has seen major progress in the recent years, triggered by our improved understanding of the biology of the disease and the development of new therapies. Based on this there are multiple treatment options available for patients with WM ranging from classical immunochemotherapy to targeted approaches blocking key enzymes involved in lymphoma growth
-
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-04 Elena Fountzilas, Apostolia-Maria Tsimberidou, Henry Hiep Vo, Razelle Kurzrock
Choosing the right drug(s) for the right patient via advanced genomic sequencing and multi-omic interrogation is the of precision cancer medicine. Traditional cancer clinical trial designs follow well-defined protocols to evaluate the efficacy of new therapies in patient groups, usually identified by their histology/tissue of origin of their malignancy. In contrast, precision medicine seeks to optimize
-
Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-01 K.R.J. Kistemaker, F. Sijani, D.J. Brinkman, A. de Graeff, G.L. Burchell, M.A.H. Steegers, L. van Zuylen
Cancer-related pain often requires opioid treatment with opioid-induced constipation (OIC) as its most frequent gastrointestinal side-effect. Both for prevention and treatment of OIC osmotic (e.g. polyethylene glycol) and stimulant (e.g. bisacodyl) laxatives are widely used. Newer drugs such as the peripherally acting µ-opioid receptor antagonists (PAMORAs) and naloxone in a fixed combination with
-
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-27 Michele Bartoletti, Marcella Montico, Domenica Lorusso, Roberta Mazzeo, Ana Oaknin, Lucia Musacchio, Giovanni Scambia, Fabio Puglisi, Sandro Pignata
Various randomized trials have explored the efficacy of combining immune checkpoint inhibitors (ICIs) with first-line chemotherapy in advanced endometrial cancer. We aimed to summarize available data and clarify the benefit of adding immunotherapy according to the DNA mismatch repair status (deficient, dMMR or proficient, pMMR) and the specific type of agent used (anti-PD1 or anti-PD-L1). To assess
-
Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-25 David Johnson, Cheng Ean Chee, Wesley Wong, Rachel C.T. Lam, Iain Bee Huat Tan, Brigette B.Y. Ma
The last two decades have witnessed major breakthroughs in the development of targeted therapy for patients with metastatic colorectal cancer (mCRC), an achievement which stems largely from advances in translational research. Precision medicine is now widely practiced in routine oncological care, where systemic therapy is individualized based on clinical factors such as primary tumor sidedness, location
-
177Lu-PSMA therapy in metastatic prostate cancer: an updated review of prognostic and predictive biomarkers Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-17 Emilio Francesco Giunta, Nicole Brighi, Giorgia Gurioli, Federica Matteucci, Giovanni Paganelli, Ugo De Giorgi
177Lu-PSMA has been approved for the treatment of PSMA-positive metastatic castration-resistant (mCRPC) patients who progressed to androgen receptor pathway inhibitors (ARPIs) and taxane-based chemotherapy. However, a higher proportion of patients do not respond to this type of radioligand therapy (RLT). To date, there is a lack of validated prognostic and predictive biomarkers for 177Lu-PSMA therapy
-
Salivary gland carcinoma: Towards a more personalised approach Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-12 Layal Rached, Khalil Saleh, Odile Casiraghi, Caroline Even
Salivary Gland carcinomas (SGCs) are rare tumors accounting for less than 1% of all cancers with 21 histologically diverse subtypes. The rarity of the disease presents a challenge for clinicians to conduct large size randomized controlled trials. Surgery and radiotherapy remain the only curative treatment for localized disease, whereas treatments for recurrent and metastatic disease remain more challenging
-
Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-11 Matteo Bauckneht, Chiara Ciccarese, Riccardo Laudicella, Claudia Mosillo, Francesca D'Amico, Annunziato Anghelone, Alessandro Strusi, Viria Beccia, Sergio Bracarda, Giuseppe Fornarini, Giampaolo Tortora, Roberto Iacovelli
In the last years, theranostics has expanded the therapeutic options available for prostate cancer patients. In this review, we explore this dynamic field and its potential to revolutionize precision medicine for prostate cancer. We delve into the foundational principles, clinical applications, and emerging opportunities, emphasizing the potential synergy between radioligand therapy and other systemic
-
Preoperative chemotherapy in upfront resectable colorectal liver metastases: New elements for an old dilemma? Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-07 Lorenzo Bernardi, Raffaello Roesel, Davit L. Aghayan, Pietro E. Majno-Hurst, Sara De Dosso, Alessandra Cristaudi
The use of preoperative or “neoadjuvant” chemotherapy (NAC) has long been controversial for resectable colorectal liver metastases (CRLM). The European Society of Medical Oncology (ESMO) 2023 guidelines on metastatic colorectal cancer (CRC) indicate a combination of surgical/technical and oncologic/prognostic criteria as the two determinants for allocating patients to NAC or upfront hepatectomy. However
-
High-dose chemotherapy for Ewing sarcoma and Rhabdomyosarcoma: A systematic review by the Australia and New Zealand sarcoma association clinical practice guidelines working party Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-02 Ashika Ramamurthy, Elizabeth A Connolly, Jasmine Mar, Jeremy Lewin, Vivek A Bhadri, Marianne B Phillips, Mark Winstanley, Lisa M Orme, Peter Grimison, Joanna Connor, Smaro Lazarakis, Angela M Hong, Natacha Omer, Julie Cayrol
Patients with high-risk or metastatic Ewing sarcoma (ES) and rhabdomyosarcoma (RMS) have a guarded prognosis. High-dose chemotherapy (HDT) with autologous stem cell transplant (ASCT) has been evaluated as a treatment option to improve outcomes. However, survival benefits remain unclear, and treatment is associated with severe toxicities. A systematic review was conducted, using the population, intervention
-
A conceptual framework for cautious escalation of anticancer treatment: how to optimize overall benefit and obviate the need for de-escalation trials Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-01-30 I. Pourmir, Hk. Van Halteren, R. Elaidi, D. Trapani, F. Strasser, G. Vreugdenhil, M. Clarke
Background The developmental workflow of the currently performed phase 1, 2 and 3 cancer trial stages lacks essential information required for the determination of the optimal efficacy threshold of new anticancer regimens. Due to this there is a serious risk of overdosing and/or treating for an unnecessary long time, leading to excess toxicity and a higher financial burden for society. But often post-approval
-
Challenges to genetic testing for germline mutations associated with breast cancer among African Americans Authors Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-01 S. Kamaraju, M. Conroy, A. Harris, M. Georgen, H. Min, M. Powell, R. Kurzrock
-
How To Deal With Renal Toxicities From Immune-Based Combination Treatments In Metastatic Renal Cell Carcinoma. A Nephrological Consultation For Oncologists Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-01-23 Tucci Marcello, Cosmai Laura, Pirovano Marta, Campisi Ilaria, Re Sartò Giulia Vanessa, Porta Camillo, Gallieni Maurizio, Piergiorgio Messa
-
-
Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-01-17 Javier Munoz, Anagha Deshpande, Lisa Rimsza, Grzegorz S. Nowakowski, Razelle Kurzrock
In treating diffuse large B-cell lymphoma (DLBCL), oncologists have traditionally relied on the chemotherapy backbone of R-CHOP as standard of care. The two dangers that the hematologist must navigate between are the aggressive disease (Charybdis that in the absence of therapy systematically destroys all the ships) and the toxicity of the therapies (Scylla with its six monstrous heads that devours
-
Optimizing lung cancer radiation therapy: A systematic review of multifactorial risk assessment for radiation-induced lung toxicity Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-01-13 Rayan Bensenane, Sylvie Helfre, Kim Cao, Matthieu Carton, Laurence Champion, Nicolas Girard, Matthieu Glorion, Thibaut Vieira, Waisse Waissi, Gilles Crehange, Arnaud Beddok
Background Radiation therapy (RT) is essential in treating advanced lung cancer, but may lead to radiation pneumonitis (RP). This systematic review investigates the use of pulmonary function tests (PFT) and other parameters to predict and mitigate RP, thereby improving RT planning. Methods A systematic review sifted through PubMed and on BioMed Central, targeting articles from September 2005 to December
-
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-01-12 Davide Ciardiello, Gianluca Mauri, Andrea Sartore-Bianchi, Salvatore Siena, Maria Giulia Zampino, Nicola Fazio, Andres Cervantes
Despite recent molecular and immunological advancements, prognosis of metastatic colorectal cancer (mCRC) patients remains poor. In this context, several retrospective and phase II studies suggested that after failure of an upfront anti-EGFR based regimen, a subset of patients can still benefit from further anti-EGFR blockade. Several translational studies involving circulating tumor DNA (ctDNA) analysis
-
Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-25 Rebecca Ibrahim, Tarek Assi, Rita Khoury, Carine Ngo, Matthieu Faron, Benjamin Verret, Antonin Lévy, Charles Honoré, Clémence Hénon, Cécile Le Péchoux, Ratislav Bahleda, Axel Le Cesne
Desmoid tumors (DT) are rare, slow-growing, locally invasive soft tissue tumors that often pose significant therapeutic challenges. Traditional management strategies including active surveillance, surgery, radiotherapy, and systemic therapy which are associated with varying recurrence rates and high morbidity. Given the challenging nature of DT and the modest outcomes associated with current treatment
-
Histology independent drug development – Is this the future for cancer drugs? Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-23 Lucinda Billingham, Lynn Brown, Theodor Framke, Alastair Greystoke, Eivind Hovig, Siddhartha Mathur, Philippe Page, Elias Pean, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Richardus Vonk, Sacha Wissink, Hilke Zander, Ruth Plummer
The Cancer Drug Development Forum (CDDF)’s ‘Histology independent drug development – is this the future for cancer drugs?’ workshop was set up to explore the current landscape of histology independent drug development, review the current regulatory landscape and propose recommendations for improving the conduct of future trials. The first session considered lessons learnt from previous trials, including
-
Neoadjuvant chemotherapy for early-stage colon cancer Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-23 Alessandro Audisio, Roberta Fazio, Valentina Daprà, Irene Assaf, Alain Hendlisz, Francesco Sclafani
Surgery with or without adjuvant chemotherapy is the standard treatment for early-stage colon cancer. However, evidence has recently emerged for neoadjuvant chemotherapy, with the results of randomised clinical trials sparking debates within multidisciplinary teams and splitting the gastrointestinal oncology community. Further to a systematic search of the literature, we provide a thorough and in-depth
-
The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-20 Miriam Dorta-Suárez, Maria de Miguel, Oscar Amor-Carro, José Miguel Calderón, MCarmen González-Ortega, Delvys Rodríguez-Abreu
Insertions in the epidermal growth factor receptor (EGFR) exon 20 (Ex20Ins) are the third most incident mutations in non-small cell lung cancer (NSCLC). The hypervariable nature of these driver mutations hinders their identification by traditional polymerase chain reaction (PCR)-based methods, requiring a comprehensive sequencing approach to detect all possible insertions. The prognosis of patients
-
Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-19 Almuth Maria Anni Merz, Marie Sébert, Jan Sonntag, Anne Sophie Kubasch, Uwe Platzbecker, Lionel Adès
Recent developments in high-risk Myelodysplastic Neoplasms (HR MDS) treatment are confronted with challenges in study design due to evolving drug combinations with Hypomethylating Agents (HMAs). The shift from the International Prognostic Scoring System (IPSS) to its molecular revision (IPSS-M) has notably influenced research and clinical practice. Introducing concepts like the MDS/AML overlap complicate
-
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs) Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-14 Arianna Dri, Grazia Arpino, Giampaolo Bianchini, Giuseppe Curigliano, Romano Danesi, Michelino De Laurentiis, Lucia Del Mastro, Alessandra Fabi, Daniele Generali, Alessandra Gennari, Valentina Guarneri, Daniele Santini, Edda Simoncini, Claudio Zamagni, Fabio Puglisi
Antibody-drug conjugates (ADCs) represent a novel class of molecules composed of a recombinant monoclonal antibody targeted to a specific cell surface antigen, conjugated to a cytotoxic agent through a cleavable or non-cleavable synthetic linker. The rationale behind the development of ADCs is to overcome the limitations of conventional chemotherapy, such as the narrow therapeutic window and the emergence
-
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-10 Neeta Somaiah, William Tap
Well-differentiated and dedifferentiated liposarcomas (WDLPS and DDLPS) are rare tumors that arise from lipocytes in soft tissue. There is a high unmet need in patients with these liposarcomas given poor outcomes, particularly for DDLPS. WDLPS and DDLPS share important genetic and histological characteristics – most notably, the amplification of the 2 genes MDM2 and CDK4. Both genes are considered
-
Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-10 Hatice Bolek, Emre Yekedüz, Yüksel Ürün
Introduction Immunotherapy (IO)-based combination therapies have emerged as the standard of care for first-line treatment of metastatic renal cell carcinoma (mRCC) among patients classified as intermediate and poor risk. However, in the favorable risk group, the available data remains less compelling. This study aims to assess and compare the effectiveness of IO-based combination therapies versus tyrosine
-
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-10 Luca Cantini, Dario Trapani, Lorenzo Guidi, Luca Boscolo Bielo, Roberta Scafetta, Marcin Koziej, Laura Vidal, Kamal S. Saini, Giuseppe Curigliano
Neoadjuvant therapy is commonly used in patients with locally advanced or inoperable breast cancer (BC). Neoadjuvant chemotherapy (NACT) represents an established treatment modality able to downstage tumours, facilitate breast-conserving surgery, yet also achieve considerable pathologic complete response (pCR) rates in HER2-positive and triple-negative BC. For patients with HR+/HER2- BC, the choice
-
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-09 Komal Jhaveri, Frederik Marmé
In the past decade, significant progress was made in treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC), but many clinical questions remain. Cyclin-dependent kinase 4/6 inhibitors are now widely used in combination with endocrine therapy (ET) as standard of care, having demonstrated significant progression-free survival
-
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-01 Shlomit Strulov Shachar, Yasmin Korzets, Daniel Shepshelovich, Noa Zlothover, Eitan Amir, Ariadna Tibau, Hadar Goldvaser
Background As the treatment for metastatic breast cancer (MBC) often includes sequential lines of therapy, data on post-protocol treatment in clinical trials are valuable in the assessment of long-term outcomes. The objective of this study was to assess the reported data on post-protocol therapy in clinical trials supporting US Food and Drug Administration (FDA) approval of drugs for MBC. Methods All
-
Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-11-27 Karlijn de Joode, Niels Heersche, Edwin A. Basak, Sander Bins, Astrid A.M. van der Veldt, Ron H.N. van Schaik, Ron H.J. Mathijssen
-
Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-11-27 Celine Man Ying Li, Runhao Li, Paul Drew, Timothy Price, Eric Smith, Guy J. Maddern, Yoko Tomita, Kevin Fenix
Colorectal cancer (CRC) remains a significant global health burden and is the second leading cause of cancer-related death. Cytokine induced killer (CIK) cell therapy is an immunotherapy which has the potential to meet this need. Clinical trials of CIK cell therapy for the management of CRC have reported improved clinical outcomes. However, production and delivery protocols varied significantly, and
-
A systematic review of the role of chemotherapy in retroperitoneal sarcoma by the Australia and New Zealand sarcoma association clinical practice guidelines working party Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-11-25 Deborah Di-Xin Zhou, Elizabeth A Connolly, Jasmine Mar, Smaro Lazarakis, Peter S Grimison, Joanna Connor, David E Gyorki, Angela M Hong
Background In primary localised resectable retroperitoneal sarcoma (RPS), loco-regional and distant relapse occur frequently despite optimal surgical management. The role of chemotherapy in improving outcomes is unclear. Methods A systematic review was conducted, using the population, intervention, comparison outcome (PICO) model, to evaluate whether neoadjuvant or adjuvant chemotherapy improve outcomes
-
The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-11-25 Fortunato Ciardiello, Fred R. Hirsch, Robert Pirker, Enriqueta Felip, Christian Valencia, Egbert F. Smit
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the current recommended option for the first-line treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC). Resistance to first-generation TKIs led to the development of second- and third-generation TKIs with improved clinical outcomes. However, sequential administration of TKIs has led to the emergence of
-
-
Pharmacotherapy for leptomeningeal disease in breast cancer Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-11-07 Rupert Bartsch, Katarzyna J. Jerzak, Louis Larrouquere, Volkmar Müller, Emilie Le Rhun
Clinical data supporting the best therapeutic approach in leptomeningeal disease (LMD; also known as leptomeningeal metastases or leptomeningeal carcinomatosis) are lacking. Despite the development of new agents and increasing incidence of central nervous system metastases, patients with LMD are often excluded from clinical trials in breast cancer, with very few conducted specifically in LMD. Consequently
-
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-11-04 Laurence Albiges, Bradley A. McGregor, Daniel Y.C. Heng, Giuseppe Procopio, Guillermo de Velasco, Naila Taguieva-Pioger, Lidia Martín-Couce, Nizar M. Tannir, Thomas Powles
Introduction We conducted a systematic literature review to identify evidence for use of vascular endothelial growth factor (VEGF)-targeted (anti-VEGF) treatment in patients with renal cell carcinoma (RCC) following prior checkpoint inhibitor (CPI)-based therapy. Methods This was a PRISMA-standard systematic literature review; registered with PROSPERO (CRD42021255568). Literature searches were conducted
-
Recent advances in genomics and therapeutics in mantle cell lymphoma Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-11-04 Tingxun Lu, Jie Zhang, Jenna M. McCracken, Ken H. Young
Over the past decades, significant strides have been made in understanding the pathobiology, prognosis, and treatment options for mantle cell lymphoma (MCL). The heterogeneity observed in MCL's biology, genomics, and clinical manifestations, including indolent and aggressive forms, is intricately linked to factors such as the mutational status of the variable region of the immunoglobulin heavy chain
-
Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-31 Albrecht Stenzinger, Arndt Vogel, Ulrich Lehmann, Angela Lamarca, Paul Hofman, Luigi Terracciano, Nicola Normanno
-
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-31 Lorena Incorvaia, Alessandro Perez, Claudia Marchetti, Chiara Brando, Valerio Gristina, Daniela Cancelliere, Alessia Pivetti, Silvia Contino, Emilia Di Giovanni, Nadia Barraco, Marco Bono, Ambra Giurintano, Tancredi Didier Bazan Russo, Andrea Gottardo, Sofia Cutaia, Erika Pedone, Marta Peri, Lidia Rita Corsini, Daniele Fanale, Antonio Galvano, Viviana Bazan
-
Antibody based therapies in Hodgkin lymphoma Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-28 Vivek S. Radhakrishnan, Jemma Longley, Peter W.M. Johnson
Multimodality treatment approaches, with systemic therapies at their core, have made Hodgkin Lymphoma a highly curable cancer. Unmet needs remain. Resistance to therapy manifested by refractory and relapsed disease, and treatment related short- and long-term morbidity are the key challenges. Patient outcomes have improved in the recent past with the advent of novel therapies and are borne out of a
-
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle? Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-26 Francesco Maria Venanzi, Marta Bini, Antonio Nuccio, Alessandro De Toma, Matteo Lambertini, Francesca Rita Ogliari, Sara Oresti, Maria Grazia Viganò, Elena Brioschi, Maggie Polignano, Matteo Maria Naldini, Silvia Riva, Michele Ferrara, Nicola Fogale, Giuseppe Damiano, Vincenzo Russo, Michele Reni, Giulia Veronesi, Giorgia Foggetti, Fabio Conforti, Roberto Ferrara
In the immunoncology era, growing evidence has shown a clear sex dimorphism in antitumor immune response with a potential impact on outcomes upon immunecheckpoint blockade (ICI) in patients with cancer. Sex dimorphism could affect tumor microenvironment composition and systemic anticancer immunity; however, the modifications induced by sex are heterogeneous. From a clinical perspective, six metanalyses
-
Malignant ascites: Current therapy options and treatment prospects Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-24 Julia M. Berger, Matthias Preusser, Anna S. Berghoff, Elisabeth S. Bergen
Ascites formation is a common complication of cancer with a significant symptomatic burden for patients. Malignant ascites (MA) is defined by the presence of tumor cells within the ascitic fluid. It does not only cause substantial morbidity, but is also associated with impaired survival. Considering the frequent occurrence of MA, it still represents a clinical challenge for physicians with limited
-
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-18 Nadia Harbeck, Ronald Kates, Timo Schinköthe, Johannes Schumacher, Rachel Wuerstlein, Tom Degenhardt, Diana Lüftner, Philip Räth, Oliver Hoffmann, Ralf Lorenz, Thomas Decker, Mattea Reinisch, Thomas Göhler, Peter Staib, Oleg Gluz, Peter A Fasching, Marcus Schmidt
Background Oral cancer medications offer advantages but also pose challenges for therapy management and adherence. An eHealth-based platform such as CANKADO can help to support therapy management by probing the patient’s quality of life (QoL) continuously throughout the course of treatment. Material and Methods AGO-B WSG PreCycle (NCT03220178) is a multicenter, randomized phase IV intergroup trial
-
Evolution of the HIF targeted therapy in clear cell renal cell carcinoma Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-15 Borivoj Golijanin, Kamil Malshy, Sari Khaleel, Galina Lagos, Ali Amin, Liang Cheng, Dragan Golijanin, Anthony Mega
Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, affecting hundreds of thousands of people worldwide and can affect people of any age. The pathogenesis of ccRCC is most commonly due to biallelic loss of the tumor suppressor gene VHL. VHL is the recognition subunit of an E3-ubiquitin-ligase-complex essential for degradation of the hypoxia-inducible factors (HIF) 1α and
-
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-13 Konstantinos Venetis, Francesco Pepe, Carlo Pescia, Giulia Cursano, Carmen Criscitiello, Chiara Frascarelli, Eltjona Mane, Gianluca Russo, Beatrice Taurelli Salimbeni, Giancarlo Troncone, Elena Guerini Rocco, Giuseppe Curigliano, Nicola Fusco, Umberto Malapelle
Activating mutations of the estrogen receptor alpha gene (ESR1) are common mechanisms of endocrine therapy (ET) resistance in hormone receptor-positive (HR + )/Human Epidermal Growth Factor Receptor 2 (HER2)-negative metastatic breast cancer (MBC). Recent clinical findings emphasize that both old and new generations of selective ER degraders (SERDs) demonstrate enhanced clinical effectiveness in patients
-
The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-12 Jordi Badia-Ramentol, Francisco Gimeno-Valiente, Elena Duréndez, Carolina Martínez-Ciarpaglini, Jenniffer Linares, Mar Iglesias, Andrés Cervantes, Alexandre Calon, Noelia Tarazona
Adjuvant chemotherapy following surgical intervention remains the primary treatment option for patients with localized colorectal cancer (CRC). However, a significant proportion of patients will have an unfavorable outcome after current forms of chemotherapy. While reflecting the increasing complexity of CRC, the clinical application of molecular biomarkers provides information that can be utilized
-
Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-12 Davide Smussi, Davide Mattavelli, Alberto Paderno, Cristina Gurizzan, Luigi Lorini, Chiara Romani, Eliana Bignotti, Alberto Grammatica, Marco Ravanelli, Paolo Bossi
The treatment of locally advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC) is based on surgery followed by (chemo)radiation or on curative (chemo)radiation, depending on site and stage. Despite optimal locoregional treatment, about 50% of patients recur, with a huge impact on prognosis and substantial morbidity. The advent of immunotherapy (IT) with immune checkpoint inhibitors (ICIs) changed
-
-
AXL – a new player in resistance to HER2 blockade Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-07 Anna Adam-Artigues, Enrique J. Arenas, Joaquín Arribas, Aleix Prat, Juan Miguel Cejalvo
HER2 is a driver in solid tumors, mainly breast, oesophageal and gastric cancer, through activation of oncogenic signaling pathways such as PI3K or MAPK. HER2 overexpression associates with aggressive disease and poor prognosis. Despite targeted anti-HER2 therapy has improved outcomes and is the current standard of care, resistance emerge in some patients, requiring additional therapeutic strategies
-
Engineering strategies to optimise adoptive cell therapy in ovarian cancer Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-05 Catarina Guerra, Milena Kalaitsidou, Gray Kueberuwa, Robert Hawkins, Richard Edmondson
Ovarian cancer is amongst the ten most common cancer types in women, and it is one of the leading causes of death. Despite the promising results of targeted therapies, including anti-angiogenic agents and poly (ADP-ribose) polymerase inhibitors (PARPi), the majority of patients will relapse and develop treatment resistance, implying that novel therapeutic strategies are required. Adoptive cell therapy
-
Regulatory T cells in gastric cancer: Key controllers from pathogenesis to therapy Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-09-23 Ion Negura, Mariana Pavel-Tanasa, Mihai Danciu
Gastric cancer (GC) is a highly aggressive malignancy that remains a significant contributor to cancer-related mortality worldwide, despite a decline in incidence in recent years. Early-stage GC poses a diagnostic challenge due to its asymptomatic nature, leading to poor prognoses for most patients. Conventional treatment approaches, including chemotherapy and surgery, have shown limited efficacy in
-
Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-09-27 Jason A. Efstathiou, Alicia K. Morgans, Christopher S. Bland, Neal D. Shore
Biochemical recurrence (BCR) occurs in 20–50% of patients with prostate cancer (PCa) undergoing primary definitive treatment. Patients with high-risk BCR have an increased risk of metastatic progression and subsequent PCa-specific mortality, and thus could benefit from treatment intensification. Given the increasing complexity of diagnostic and therapeutic modalities, multidisciplinary care (MDC) can
-
Managing postoperative biochemical relapse in prostate cancer, from the perspective of the Francophone group of Urological radiotherapy (GFRU) Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-09-16 Loic Ah-Thiane, Paul Sargos, Olivier Chapet, Marjory Jolicoeur, Mario Terlizzi, Carl Salembier, Jihane Boustani, Célia Prevost, Sonya Gaudioz, Talar Derashodian, Samuel Palumbo, Olivier De Hertogh, Gilles Créhange, Thomas Zilli, Stéphane Supiot
-
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-09-19 Fenneke Zwierenga, Bianca A.M.H. van Veggel, Anke van den Berg, Harry J.M. Groen, Lili Zhang, Matthew R. Groves, K. Kok, E.F. Smit, T. Jeroen N. Hiltermann, Adrianus J. de Langen, Anthonie J. van der Wekken
Activating EGFR mutations are commonly observed in non-small cell lung cancer (NSCLC). About 4–10 % of all activating epidermal growth factor receptor (EGFR) mutations are heterogenous in-frame deletion and/or insertion mutations clustering within exon 20 (EGFRex20+). NSCLC patients with EGFRex20+ mutations are treated as a single disease entity, irrespective of the type and location of the mutation
-
Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-09-16 Angela Lamarca, Lorena Ostios, Mairéad G. McNamara, Carlos Garzon, Jack P. Gleeson, Julien Edeline, Ana Herrero, Richard A. Hubner, Victor Moreno, Juan W. Valle
Precision medicine is a major achievement that has impacted on management of patients diagnosed with advanced cholangiocarcinoma (CCA) over the last decade. Molecular profiling of CCA has identified targetable alterations, such as fibroblast growth factor receptor-2 (FGFR-2) fusions, and has thus led to the development of a wide spectrum of compounds. Despite favourable response rates, especially with
-
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design? Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-09-15 Roelof van Ewijk, Morgane Cleirec, Nikolas Herold, Marie-Cécile le Deley, Natasha van Eijkelenburg, Pascaline Boudou-Rouquette, Séverine Risbourg, Sandra J. Strauss, Emanuela Palmerini, Kjetil Boye, Leo Kager, Stefanie Hecker-Nolting, Antonin Marchais, Nathalie Gaspar
Background/Objective To analyze changes in recurrent/refractory osteosarcoma phase II trials over time to inform future trials in this population with poor prognosis. Methods A systematic review of trials registered on trial registries between 01/01/2017–14/02/2022. Comparison of 98 trials identified between 2003 and 2016. Publication search/analysis for both periods, last update on 01/12/2022. Results
-
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-09-09 Angela Contri, Sara Paltrinieri, Martina Torreggiani, Maria Chiara Bassi, Elisa Mazzini, Monica Guberti, Isabella Campanini, Luca Ghirotto, Stefania Fugazzaro, Stefania Costi
As the number of cancer survivors (CSs) is increasing worldwide, providing services relevant to the specific, unmet needs of these individuals is crucial. There are currently various patient-reported outcome measures (PROMs) whose aim is to identify the unmet needs of CSs. Still, limited guidance supports healthcare providers in choosing the most valid and reliable PROMs for this purpose. We conducted
-
Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-09-09 Giovanni Maria Iannantuono, Elias Chandran, Charalampos S. Floudas, Hyoyoung Choo-Wosoba, Gisela Butera, Mario Roselli, James L. Gulley, Fatima Karzai
Introduction PARP inhibitors (PARPi) are a standard-of-care (SoC) treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). Several clinical trials have shown the potential of combining PARPi with other anticancer agents. Therefore, we conducted a systematic review and meta-analysis to comprehensively evaluate the efficacy and safety of PARPi in patients with metastatic